MY127734A - Pharmaceutical compositions comprising a farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer - Google Patents
Pharmaceutical compositions comprising a farnesyl transferase inhibiting 1,2-annelated quinoline enantiomerInfo
- Publication number
- MY127734A MY127734A MYPI20012896A MYPI20012896A MY127734A MY 127734 A MY127734 A MY 127734A MY PI20012896 A MYPI20012896 A MY PI20012896A MY PI20012896 A MYPI20012896 A MY PI20012896A MY 127734 A MY127734 A MY 127734A
- Authority
- MY
- Malaysia
- Prior art keywords
- pharmaceutical compositions
- farnesyl transferase
- transferase inhibiting
- quinoline enantiomer
- annelated quinoline
- Prior art date
Links
- 102000007317 Farnesyltranstransferase Human genes 0.000 title 1
- 108010007508 Farnesyltranstransferase Proteins 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00202181 | 2000-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY127734A true MY127734A (en) | 2006-12-29 |
Family
ID=8171675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI20012896A MY127734A (en) | 2000-06-22 | 2001-06-20 | Pharmaceutical compositions comprising a farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US20030114471A1 (https=) |
| EP (1) | EP1296984B1 (https=) |
| JP (1) | JP4919575B2 (https=) |
| KR (2) | KR100846370B1 (https=) |
| CN (1) | CN1207296C (https=) |
| AR (1) | AR030704A1 (https=) |
| AT (1) | ATE294804T1 (https=) |
| AU (3) | AU2001263962B2 (https=) |
| BG (1) | BG65894B1 (https=) |
| BR (1) | BRPI0111743B8 (https=) |
| CA (1) | CA2410232C (https=) |
| CZ (1) | CZ295278B6 (https=) |
| DE (1) | DE60110592T2 (https=) |
| EA (1) | EA005065B1 (https=) |
| EE (1) | EE04966B1 (https=) |
| EG (1) | EG24180A (https=) |
| ES (1) | ES2241830T3 (https=) |
| HR (1) | HRP20020989B1 (https=) |
| HU (1) | HU229095B1 (https=) |
| IL (2) | IL153560A0 (https=) |
| IS (1) | IS2596B (https=) |
| JO (1) | JO2361B1 (https=) |
| MX (1) | MXPA02012845A (https=) |
| MY (1) | MY127734A (https=) |
| NO (1) | NO324494B1 (https=) |
| NZ (1) | NZ522481A (https=) |
| PA (1) | PA8519501A1 (https=) |
| PL (1) | PL209521B1 (https=) |
| SA (1) | SA01220349B1 (https=) |
| SK (1) | SK285699B6 (https=) |
| UA (1) | UA73572C2 (https=) |
| WO (1) | WO2001098302A1 (https=) |
| ZA (1) | ZA200210305B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003018135A1 (en) * | 2001-08-24 | 2003-03-06 | Wyeth Holdings Corporation | Method of using 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase |
| DE60307616T2 (de) | 2002-04-15 | 2007-10-04 | Janssen Pharmaceutica N.V. | Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen |
| US20050003422A1 (en) | 2003-07-01 | 2005-01-06 | Mitch Reponi | Methods for assessing and treating cancer |
| US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| WO2016090107A2 (en) * | 2014-12-04 | 2016-06-09 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| WO2016172342A1 (en) | 2015-04-21 | 2016-10-27 | Eiger Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising lonafarnib and ritonavir |
| HUE044698T2 (hu) | 2015-08-17 | 2019-11-28 | Kura Oncology Inc | Kezelési módszer rákos páciensek kezelésére farnezil-transzferáz inhibitorokkal |
| JP2019534290A (ja) | 2016-11-03 | 2019-11-28 | クラ オンコロジー， インコーポレイテッド | 癌の治療方法において使用するためのファルネシルトランスフェラーゼ阻害剤 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1519765A (en) * | 1974-09-05 | 1978-08-02 | Ici Ltd | Pesticidal dihydrotetrazolo(1,5a) quinazolines compositions and processes |
| US4141979A (en) * | 1976-12-23 | 1979-02-27 | Pfizer Inc. | Tetrazolo[a]quinazol-5-ones antiallergy and antiulcer agents |
| GB9513577D0 (en) * | 1995-07-04 | 1995-09-06 | Brotherwood Rodney J | Improvements in passenger carrying vehicles |
| TW349948B (en) * | 1995-10-31 | 1999-01-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 2-quinolone derivatives |
| DE69620445T2 (de) * | 1995-12-08 | 2002-12-12 | Janssen Pharmaceutica N.V., Beerse | (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren |
| JP2000507955A (ja) | 1996-04-03 | 2000-06-27 | メルク エンド カンパニー インコーポレーテッド | ファルネシル―タンパク質転移酵素の阻害剤 |
| TW591030B (en) * | 1997-03-10 | 2004-06-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles |
| RU2205831C2 (ru) * | 1997-04-25 | 2003-06-10 | Янссен Фармацевтика Н.В. | Хиназолиноны, ингибирующие фарнезилтрансферазу |
| CN100525766C (zh) | 1997-06-02 | 2009-08-12 | 詹森药业有限公司 | 用作平滑肌细胞增殖抑制剂的（咪唑-5-基）甲基-2-喹啉酮衍生物 |
| PL193464B1 (pl) * | 1998-07-06 | 2007-02-28 | Janssen Pharmaceutica Nv | Zastosowanie inhibitora białkowej transferazy farnezylowej |
| HRP20000904A2 (en) | 1998-07-06 | 2001-12-31 | Janssen Pharmaceutica Nv | Farnesyl protein transferase inhibitors for treating arthropathies |
| TR200101343T2 (tr) * | 1998-08-27 | 2001-09-21 | Pfizer Products Inc. | Kansere karşı kullanılan maddeler olarak alkinil-ikame edilmiş kinolin-2-on türevleri |
| DE69923849T2 (de) * | 1998-08-27 | 2006-01-12 | Pfizer Products Inc., Groton | Quinolin-2-on-derivate verwendbar als antikrebsmittel |
| DK1140935T3 (da) * | 1998-12-23 | 2003-09-01 | Janssen Pharmaceutica Nv | 1,2-anellerede quinolinderivater |
| US6462201B1 (en) * | 1998-12-29 | 2002-10-08 | Isp Investments Inc. | Process for the production of N-vinyl-2-pyrrolidone by vinylation |
| SK11002001A3 (sk) * | 1999-02-11 | 2002-05-09 | Pfizer Products Inc. | Heteroarylom substituované chinolin-2-ónové deriváty použiteľné ako protinádorové prostriedky |
| HN2000000266A (es) | 2000-01-21 | 2001-05-21 | Pfizer Prod Inc | Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto. |
| ATE375794T1 (de) * | 2000-02-24 | 2007-11-15 | Janssen Pharmaceutica Nv | Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs |
| WO2002024686A2 (en) | 2000-09-25 | 2002-03-28 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives |
| US7067531B2 (en) | 2000-09-25 | 2006-06-27 | Angibaud Patrick Rene | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives |
-
2001
- 2001-05-29 JO JO200183A patent/JO2361B1/en active
- 2001-06-13 UA UA20021210152A patent/UA73572C2/uk unknown
- 2001-06-13 EP EP01938263A patent/EP1296984B1/en not_active Expired - Lifetime
- 2001-06-13 CZ CZ2003114A patent/CZ295278B6/cs not_active IP Right Cessation
- 2001-06-13 IL IL15356001A patent/IL153560A0/xx unknown
- 2001-06-13 EE EEP200200695A patent/EE04966B1/xx unknown
- 2001-06-13 AU AU2001263962A patent/AU2001263962B2/en not_active Expired
- 2001-06-13 PL PL358918A patent/PL209521B1/pl unknown
- 2001-06-13 AU AU6396201A patent/AU6396201A/xx active Pending
- 2001-06-13 US US10/312,301 patent/US20030114471A1/en not_active Abandoned
- 2001-06-13 EA EA200300048A patent/EA005065B1/ru not_active IP Right Cessation
- 2001-06-13 MX MXPA02012845A patent/MXPA02012845A/es active IP Right Grant
- 2001-06-13 NZ NZ522481A patent/NZ522481A/en not_active IP Right Cessation
- 2001-06-13 CN CNB018113788A patent/CN1207296C/zh not_active Expired - Lifetime
- 2001-06-13 KR KR1020077026608A patent/KR100846370B1/ko not_active Expired - Lifetime
- 2001-06-13 DE DE60110592T patent/DE60110592T2/de not_active Expired - Lifetime
- 2001-06-13 BR BRPI0111743-2 patent/BRPI0111743B8/pt not_active IP Right Cessation
- 2001-06-13 AT AT01938263T patent/ATE294804T1/de active
- 2001-06-13 SK SK50-2003A patent/SK285699B6/sk not_active IP Right Cessation
- 2001-06-13 HR HR20020989A patent/HRP20020989B1/xx not_active IP Right Cessation
- 2001-06-13 CA CA002410232A patent/CA2410232C/en not_active Expired - Lifetime
- 2001-06-13 JP JP2002504258A patent/JP4919575B2/ja not_active Expired - Lifetime
- 2001-06-13 HU HU0300872A patent/HU229095B1/hu unknown
- 2001-06-13 ES ES01938263T patent/ES2241830T3/es not_active Expired - Lifetime
- 2001-06-13 WO PCT/EP2001/006747 patent/WO2001098302A1/en not_active Ceased
- 2001-06-13 KR KR1020027014678A patent/KR100831940B1/ko not_active Expired - Lifetime
- 2001-06-14 PA PA20018519501A patent/PA8519501A1/es unknown
- 2001-06-20 MY MYPI20012896A patent/MY127734A/en unknown
- 2001-06-20 EG EG20010660A patent/EG24180A/xx active
- 2001-06-21 AR ARP010102954A patent/AR030704A1/es not_active Application Discontinuation
- 2001-09-10 SA SA01220349A patent/SA01220349B1/ar unknown
-
2002
- 2002-10-25 IS IS6590A patent/IS2596B/is unknown
- 2002-11-25 BG BG107310A patent/BG65894B1/bg unknown
- 2002-12-16 NO NO20026032A patent/NO324494B1/no not_active IP Right Cessation
- 2002-12-19 ZA ZA200210305A patent/ZA200210305B/en unknown
- 2002-12-19 IL IL153560A patent/IL153560A/en not_active IP Right Cessation
-
2006
- 2006-09-20 AU AU2006220405A patent/AU2006220405B2/en not_active Expired
-
2007
- 2007-01-31 US US11/669,587 patent/US8329714B2/en not_active Expired - Lifetime
- 2007-10-29 US US11/926,741 patent/US8318753B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP20053530B (en) | Tyrosine Kinase Inhibitors, Pharmaceutical Compositions Containing Them and Use Thereof | |
| GEP20053673B (en) | Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents | |
| GEP20053479B (en) | Pyrrolo[2,3-d]Pyrimidine Compounds, Pharmaceutical Composition Containing the Same and Use | |
| GEP20053595B (en) | Cyclopentanoindoles, Compositions Containing Such Compounds and Methods of Treatment | |
| MY141739A (en) | Substituted quinazoline derivatives as inhibitors of aurora kinases | |
| GEP20043324B (en) | Purine Derivatives | |
| HUP0202319A3 (en) | Use of mek inhibitors for the preparation of pharmaceutical compositions treating chronic pain | |
| TNSN03144A1 (en) | Pyrrolopyrimidines as protein kinase inhibitors | |
| GEP20053688B (en) | Substituted-Triazolopyrimidines as Anticancer Agents | |
| IL162294A0 (en) | Formulation & dosage form for the controlled delivery of therapeutic agents | |
| WO2000021515A3 (en) | Intranasal codeine for the rapid suppression of cough and rapid relief of pain | |
| AU7031500A (en) | Therapeutic quinazoline compounds | |
| IL158668A0 (en) | Deuterated 3-piperidinopropiophenone and medicaments containing said compounds | |
| AP2003002929A0 (en) | Pyrrolopyrimidines as protein kinase inhibitors | |
| NZ514129A (en) | Tolperison-containing, pharmaceutical preparation for oral administration | |
| SE9901573D0 (sv) | New compounds | |
| MY127734A (en) | Pharmaceutical compositions comprising a farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer | |
| AU2972701A (en) | 3-aminopyrazole inhibitors of cyclin dependent kinases | |
| WO2001030331A3 (en) | Therapeutic compositions including protein kinase c inhibitors | |
| IL151553A0 (en) | Orally administered controlled delivery system for once daily administration of ciprofloxacin | |
| TW200503683A (en) | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain | |
| HK1042493A1 (zh) | 新的化合物 | |
| MY122477A (en) | Sertraline oral concentrate | |
| MY133438A (en) | Morpholinobenzamide salts | |
| YU25202A (sh) | Supstituisani piroli kao antiproliferativna sredstva za lečenje kancera |